超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

中國生物制藥 Sino Biopharmaceutical
中國生物制藥有限公司于二零零零年二月二日在開曼群島注冊成立之有限公司。本公司二零零零年九月二十九日在香港聯合交易所創業板上市并于二零零三年十二月八日成功轉至香港聯合交易所主板上市，股份代號為1177。

本集團擁有優秀的制藥企業管理和研發人才，擁有全國性的藥品銷售網絡，擁有一流的已通過中國國家藥品監督局GMP認證的：大容量注射劑、大容量注射劑(非PVC)、小容量注射劑、片劑、膠囊、顆粒劑、散劑等生產設施。

本集團的宗旨是透過不斷開發創新生物藥品及中藥現代制劑，為病人帶來健康，為股東創造價值。

本集團產品主要醫療領域為肝病、心腦血管疾病、老年病等。本集團也正在發展癌癥、鎮痛和呼吸道治療領域的藥物，以滿足市場和廣大的醫生及患者的需要。

本公司主要下屬公司為：
江蘇正大天晴制藥有限公司
北京泰德制藥有限公司
南京正大天晴制藥有限公司
江蘇正大豐海制藥有限公司
青島正大海爾制藥有限公司
江蘇正大清江制藥有限公司
正大邵陽骨傷科醫院
上海通用藥業股份有限公司
北京正大綠洲醫藥科技有限公司
 

憑借本集團多年來專注發展中國醫藥市場，尤以開發獨家及專利藥為主，掌握市場信息之余亦具備完善的銷售網絡，已成為國內重點醫藥企業之一。根據北京集琦醫藥網絡有限公司最新公布的二零零五年中國醫藥統計報表數據顯示，本集團附屬公司江蘇正大天晴藥業股份公司（「江蘇正大天晴」）、共同控制公司北京泰德制藥有限公司（「北京泰德」）、長期投資公司正大青春寶藥業有限公司（「正大青春寶」），按利潤總額排名進一步向前推進，已擠身前五十強，可見本集團超卓的盈利能力。

美國《福布斯》(Forbes)將本公司評為2005年亞太地區10億美元以下最佳公司之一。

Sino Biopharmaceutical Limited incorporated in the Cayman Islands with limited liability on 2 February, 2000. On 29 September 2000, the Company was listed on GEM of the Stock Exchange in Hong Kong and successfully commenced dealings in the Shares on the Main Board in Hong Kong on Dec 8, 2003 . Its ordinary shares are traded under the stock code 1177.

The Group has excellent talents specialized in management and R&D and a countrywide product sales network. The first-class production facilities for the volume injections, small volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines and granulated medicines, etc. have obtained the GMP certification from State Food and Drug Administration.

The Group's aims to bring healthier lives to people and greater value to its shareholders by developing innovative biopharmaceuticals and modernized Chinese medicines.

The Group produces medicines in two core therapeutic categories: cardio cerebral diseases and hepatitis. And it is extending development efforts to oncology, analgesic and respiratory medicines, in order to meet the increasing demands of medical practitioners and patients.

Main subsidiaries or jointly controlled entities:

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.

Beijing Tide Pharmaceutical Co., Ltd.

Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Qingdao Chia Tai Haier Pharmaceutical Co., Ltd.

Jiangsu Chia Tai Qing Jiang Pharmaceutical Co., Ltd.

Chia Tai Shaoyang Orthopedic Hospital

Shanghai General Pharmaceutical Co., Ltd.

Beijing Chia Tai Green Continent Pharmaceutical Co., Ltd.

Being one of the most prominent pharmaceutical enterprises in the PRC, the Group's core competencies include its strategic focus on the Chinese pharmaceutical market, its abilities to develop exclusive proprietary drugs, to effectively collect market information, and to operate a comprehensive sales network. According to the Chinese Medicine Annual Report 2005 issued by Beijing JiQi, the Group's subsidiaries and its jointly-controlled entity, namely Jiangsu Chia Tai Tianqing Pharmaceutical Co. Ltd. (JCTT), Beijing Tide Pharmaceutical Co. Ltd. (Beijing Tide), and Chia Tai Qingchunbao Pharmaceutical Co. Ltd (the Group's long-term investment), all ranked amongst the top fifty enterprises in the industry in terms of profitability.

Forbes selected the Group as one of the Best 2005 Asian Companies Under A Billion.